Shenzhen Chipscreen Biosciences (688321) Fundamentals 2026 — P/E 124.9x, Revenue Analysis | SniperIQ
Shenzhen Chipscreen Biosciences (688321) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥13.2B, trading at ¥29.75 on the SHH. This SniperIQ fundamentals page covers Shenzhen Chipscreen Biosciences's valuation (P/E 124.9x, P/B 4.9x), profitability (net margin 9.8%), revenue (¥908M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen Chipscreen Biosciences's market cap?
Shenzhen Chipscreen Biosciences (688321) has a market capitalization of approximately ¥13.2B, trading at ¥29.75 on the SHH. Market cap moves with the live share price.
What is Shenzhen Chipscreen Biosciences's P/E ratio?
Shenzhen Chipscreen Biosciences's trailing twelve-month P/E ratio is 124.9x, with a price-to-book (P/B) of 4.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen Chipscreen Biosciences?
Shenzhen Chipscreen Biosciences runs a net profit margin of 9.8%, a gross margin of 86.4%, and an operating margin of 10.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen Chipscreen Biosciences generate?
Shenzhen Chipscreen Biosciences reported revenue of ¥908M for fiscal year 2025, with net income of ¥51M and earnings per share (EPS) of 0.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen Chipscreen Biosciences pay a dividend?
Shenzhen Chipscreen Biosciences offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen Chipscreen Biosciences financially healthy?
Shenzhen Chipscreen Biosciences carries a debt-to-equity ratio of 0.46x and a current ratio of 2.56x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen Chipscreen Biosciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen Chipscreen Biosciences (688321) the key facts are: market cap ¥13.2B, P/E 124.9x, revenue ¥908M, 52-week range 23.41-44.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen Chipscreen Biosciences's full fundamentals live
Get Shenzhen Chipscreen Biosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.